How Math Is Reshaping Mesothelioma Chemotherapy

This study demonstrates the feasibility of this approach since both preliminary encouraging signs of activity and no unexpected toxicities were observed, in this heavily pre-treated patients’ population.” Study Size and Rarity of Mesothelioma Present Challenges As a phase I clinical trial, it is a novel approach at this point but a promising step for future chemotherapy treatment plan protocols. The limited number of patients in the study — nine NSCLC and three mesothelioma — is also problematic, but the planned second phase of the study will include the new model’s effect on the immune system as well as additional data from other vinorelbine clinical trials. Barlesi said any possible differences in chemotherapy schedules between mesothelioma and NSCLC patients is “too difficult to say” at this point given the low number of mesothelioma patients in the phase I study. “At this time, we are focusing on tolerance, [pharmacokinetic] data and inter or intrapatients variability,” Barlesi said. “We’ll study preliminary efficacy and then decide if we should go to specific cohorts especially in mesothelioma patients.” The post How Math Is Reshaping Mesothelioma Chemotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Aix-Marseille University anemia chemotherapy best vinorelbine regimen chemotherapy side effects Fabrice Barlesi low-dose oral chemotherapy drugs math cancer chemotherapy math to fight cancer mathematical modeling cancer mesothelioma chem Source Type: news